A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy (IBCSG48-POSITIVE)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: breast cancer | Early Breast Cancer
Age: Between 18 - 42 Years
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Has received adjuvant endocrine therapy (SERM alone, GnRH analogue plus SERM or AI) for ≥18 months but ≤30 months for early breast cancer. Note: Patients who have received neo/adjuvant endocrine treatment within a clinical trial and patients who have received pharmaco-prevention are eligible.
- Patient wishes to become pregnant. Note: Patients who have undergone oocyte/embryo/ovarian tissue cryopreservation at breast cancer diagnosis and/or have a previous history of assisted reproductive technology (ART) are eligible.
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required